SCHEMBL19226459

SCHEMBL19226459

CCN1CCCC2(CCCCN2)C1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.41
TSHR P16473 1/20 0.39
CDC42BPB Q9Y5S2 11/20 0.33
ROCK1 Q13464 10/20 0.33
DDR1 Q08345 1/20 0.32
PDCD1LG2 Q9BQ51 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
CDC42BPA Q5VT25 7/20 0.32
ROCK2 O75116 7/20 0.32
CHRNA1 P02708 1/20 0.31
CHRNG P07510 1/20 0.31
CHRNB1 P11230 1/20 0.31
CHRNB2 P17787 1/20 0.31
CHRNB4 P30926 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA7 P36544 1/20 0.31
CHRNA4 P43681 1/20 0.31
CHRND Q07001 1/20 0.31
NAMPT P43490 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21364606 0.94 TSHR (0.40) SIGMAR1TSHRPDCD1LG2CD274CHRNA1
SCHEMBL24789955 0.92 TSHR (0.41) SIGMAR1TSHR
SCHEMBL12317599 0.87 TSHR (0.43) SIGMAR1TSHRCDC42BPBROCK1PDCD1LG2
SCHEMBL20037915 0.85 SIGMAR1 (0.46) SIGMAR1TSHR
SCHEMBL16306657 0.81 KDM4E (0.38) SIGMAR1TSHR
SCHEMBL12523683 0.80 SIGMAR1 (0.35) SIGMAR1TSHRPDCD1LG2CD274CHRNA1
SCHEMBL7708635 0.80 TSHR (0.43) SIGMAR1TSHR
SCHEMBL26246931 0.80 TSHR (0.47) SIGMAR1TSHRPDCD1LG2CD274CHRNB2
SCHEMBL12656466 0.76 TSHR (0.40) TSHR
SCHEMBL24851626 0.76 TSHR (0.47) SIGMAR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220402950-A1 SUBSTITUTED BENZIMIDAZOLES AS PAD4 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2022-12-22 US disclosed
US-20170226132-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402950-A1 SUBSTITUTED BENZIMIDAZOLES AS PAD4 INHIBITORS PADI4, PADI1, PADI6 SIGMAR1 4079/4885TSHR 4041/4885CDC42BPB 2896/4885
US-20170226132-A1 TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF ABL1, JAK2, JAK1 SIGMAR1 1063/4885TSHR 2621/4885CDC42BPB 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.